GENEVA & DURHAM, N.C.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”), a ...

Please provide your email address to receive an email when new articles are posted on . Rumors swirled around the exhibit floor and coursed through gatherings of dry eye disease docs who attended the ...

Narrow-moat Alcon discussed current projects and initiatives, pipeline progression, and long-term financial goals in its 2025 Capital Markets Day. After digesting the performance of each business unit ...

Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the ...

Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and ...

Please provide your email address to receive an email when new articles are posted on . Kala Pharmaceuticals has entered into a definitive agreement to sell its commercial portfolio and related assets ...

Alcon reported fourth-quarter sales growth of 8.6% and core diluted EPS growth of 4.5%, both shy of FactSet consensus estimates. Guidance for 2026 includes 6% and 10.5% growth in constant currency for ...

Alcon Laboratories, already one of the largest employers and taxpayers in Tarrant County, is exploring a major expansion of its Fort Worth campus. Alcon, which started in Fort Worth and has grown to ...